RxDoctor Payments Data

William Montesano, MD

Family Medicine · Rochester, NYNPI 1962510792

Payments from drug & device makers

$5,390in general payments, 2019–2025

Across 299 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$884
  • Novo Nordisk$532
  • Amgen$406
  • Lilly USA, LLC$385
  • GSK$289
  • Astellas Pharma US Inc$278
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,12295%
  • Education$601%
  • Other$2084%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,390 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$30,090
Medicare patients
79
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide52$65,768
FarxigaDapagliflozin Propanediol46$48,939
JardianceEmpagliflozin42$48,327
EliquisApixaban15$21,910
Atorvastatin Calcium364$6,056
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$3,254
Metformin Hcl ErMetformin Hcl190$3,138
Rosuvastatin Calcium115$2,436
Omeprazole119$2,367
Levothyroxine Sodium126$2,065
Lisinopril165$1,729
Amlodipine Besylate179$1,576
Metoprolol Succinate75$1,476
Losartan Potassium115$1,452
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$1,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$385$65,76852 claims
AstraZenecaFarxiga$267$48,93946 claims
Boehringer IngelheimJardiance$141$48,32742 claims
PfizerEliquis$256$21,91015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.

Other family medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →